Novo Nordisk’s haemophilia A drug stops bleeds in 74% of children
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/19.CcrFU5Zy.js ...
BioSpace20h
Novo’s Bispecific for Hemophilia Aces Phase III Pediatric Trial
Novo Nordisk’s bispecific antibody Mim8 prevented bleeding events and caused no adverse safety events in the Phase III FRONTIER3 trial. The company plans to file for approval this year, hoping to ...
Novo Nordisk reports interim results from late-stage trial of its haemophilia A treatment
Novo Nordisk announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia ...
ENDPOINTS NEWS23h
No­vo Nordisk takes aim at Roche in he­mo­phil­ia A, but is way be­hind
Novo Nordisk's hemophilia A drug Mim8 shows success in pediatric trial, Mim8 could compete with Roche's Hemlibra, with plans ...